By covalently binding to Cys-773/805, a cysteine residue in the ATP-binding pocket of the ErbB family (HER1/2/4), neratinib inhibits the activation of the extracellular signal-regulated kinase (ERK)/MAPK and PI3/Akt pathways and reduces the expression of cyclin D1, while upregulating the level of p27, ultimately leading to cell-cycle arrest and decreased proliferative viability of cancer cells (Booth et al., 2020; Smith et al., 2021). Here, EGFR is linked to cancer.